糖尿病：如何管理2型糖尿病患者的超重和肥胖问题。
Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus.
作者信息
Wesling Megan, D'Souza Jennifer J
机构信息
HSC College of Pharmacy, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX, USA.
Midwestern University, Downers Grove, IL, USA.
出版信息
Drugs Context. 2022 Jun 14;11. doi: 10.7573/dic.2021-11-7. eCollection 2022.
Abstract
The prevalence of obesity worldwide continues to increase substantially. Obesity is a chronic disease that can lead to other health conditions, including type 2 diabetes mellitus (T2DM). A variety of treatment options are available to treat T2DM. With its prevalence increasing, it is essential that healthcare professionals assess how their patients' current diabetes treatment is being managed to avoid further weight gain in those with overweight or obesity.
摘要
全球肥胖症的患病率持续大幅上升。肥胖是一种慢性疾病，可导致包括2型糖尿病（T2DM）在内的其他健康问题。治疗T2DM有多种选择。随着其患病率的增加，医疗保健专业人员必须评估其患者当前的糖尿病治疗管理情况，以避免超重或肥胖患者进一步体重增加。
相似文献
1
Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus.糖尿病：如何管理2型糖尿病患者的超重和肥胖问题。
Drugs Context. 2022 Jun 14;11. doi: 10.7573/dic.2021-11-7. eCollection 2022.
2
[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].[精神药物所致体重增加：关于流行病学数据、机制及管理的文献综述]
Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. doi: 10.1016/s0013-7006(05)82412-1.
3
Impact of weight gain on outcomes in type 2 diabetes.体重增加对 2 型糖尿病结局的影响。
Curr Med Res Opin. 2011 Jul;27(7):1431-8. doi: 10.1185/03007995.2011.585396. Epub 2011 May 23.
4
Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective, population-based cohort study.超重和肥胖但非体重正常的多囊卵巢综合征女性患2型糖尿病的风险增加——一项基于人群的前瞻性队列研究。
Hum Reprod. 2017 Feb;32(2):423-431. doi: 10.1093/humrep/dew329. Epub 2016 Dec 28.
5
Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.美国2型糖尿病患者中抗肥胖治疗和致体重增加的降糖药物的流行情况。
Clin Ther. 2022 Mar;44(3):e35-e44. doi: 10.1016/j.clinthera.2022.01.003. Epub 2022 Jan 30.
6
7
Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention.体重为中心的 2 型糖尿病药物治疗 - 心血管疾病预防的重要组成部分。
J Diabetes Complications. 2020 Aug;34(8):107619. doi: 10.1016/j.jdiacomp.2020.107619. Epub 2020 May 11.
9
Class 3 Obesity in a Multidisciplinary Metabolic Weight Management Program: The Effect of Preexisting Type 2 Diabetes on 6-Month Weight Loss.多学科代谢体重管理项目中的3级肥胖：既往2型糖尿病对6个月体重减轻的影响。
J Diabetes Res. 2020 Aug 1;2020:9327910. doi: 10.1155/2020/9327910. eCollection 2020.
10
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.2型糖尿病中与降糖药物相关的体重变化。
Drug Saf. 2007;30(12):1127-42. doi: 10.2165/00002018-200730120-00005.
引用本文的文献
1
Delivery of dietary messages for type 2 diabetic patients by dental practitioners: A scoping review protocol.牙科医生向2型糖尿病患者传递饮食信息：一项范围综述方案
Health Sci Rep. 2024 Oct 8;7(10):e70131. doi: 10.1002/hsr2.70131. eCollection 2024 Oct.
2
Comparison of Efficacy of Fermented Garlic and Orlistat (Lipase Inhibitor) in Obesity Management Using an Experimental Rodent Model.使用实验性啮齿动物模型比较发酵大蒜和奥利司他（脂肪酶抑制剂）在肥胖管理中的疗效。
Foods. 2023 Oct 25;12(21):3905. doi: 10.3390/foods12213905.
3
Extracts of Dunkelfelder Grape Seeds and Peel Increase the Metabolic Rate and Reduce Fat Deposition in Mice Maintained on a High-Fat Diet.深色费尔德葡萄籽和果皮提取物可提高高脂饮食小鼠的代谢率并减少脂肪沉积。
Foods. 2023 Aug 29;12(17):3251. doi: 10.3390/foods12173251.
本文引用的文献
1
ADA's Standards of Medical Care in Diabetes.美国糖尿病协会糖尿病医疗护理标准。
Clin Diabetes. 2021 Jan;39(1):128. doi: 10.2337/cd21-pe01.
2
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).在一项随机对照试验（AWARD-11）中，接受二甲双胍治疗的 2 型糖尿病患者使用 3.0mg 和 4.5mg 度拉鲁肽与 1.5mg 度拉鲁肽的疗效和安全性。
Diabetes Care. 2021 Mar;44(3):765-773. doi: 10.2337/dc20-1473. Epub 2021 Jan 4.
3
Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.阿卡波糖具有与二肽基肽酶-4 抑制剂相当的降血糖效果，但减重效果更优：一项随机对照试验的系统评价和网络荟萃分析。
Front Endocrinol (Lausanne). 2020 Jun 5;11:288. doi: 10.3389/fendo.2020.00288. eCollection 2020.
4
Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.达格列净对 2 型糖尿病合并肥胖患者心外膜脂肪厚度的影响。
Obesity (Silver Spring). 2020 Jun;28(6):1068-1074. doi: 10.1002/oby.22798. Epub 2020 Apr 30.
5
Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients.度拉糖肽在 2 型糖尿病患者真实世界和特殊人群中的疗效。
J Clin Endocrinol Metab. 2020 Jul 1;105(7). doi: 10.1210/clinem/dgaa204.
6
Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.口服司美格鲁肽：用于治疗 2 型糖尿病的首个口服 GLP-1 受体激动剂。
Ann Pharmacother. 2020 May;54(5):478-485. doi: 10.1177/1060028019889064. Epub 2019 Nov 19.
7
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).在二型糖尿病患者中，每周一次司美格鲁肽 1.0mg 与每日一次利拉鲁肽 1.2mg 作为 1-3 种口服抗糖尿病药物的附加疗法的疗效和安全性 (SUSTAIN 10)。
Diabetes Metab. 2020 Apr;46(2):100-109. doi: 10.1016/j.diabet.2019.101117. Epub 2019 Sep 17.
8
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.在伴有或不伴有二甲双胍的胰岛素治疗基础上加用口服司美格鲁肽与安慰剂治疗 2 型糖尿病患者的疗效、安全性和耐受性：PIONEER 8 试验。
Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17.
9
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.度拉糖肽扩展剂量范围的疗效和安全性：二甲双胍治疗 2 型糖尿病患者的 2 期、安慰剂对照试验。
Diabetes Obes Metab. 2019 Sep;21(9):2048-2057. doi: 10.1111/dom.13764. Epub 2019 Jun 3.
10
Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.在 2 型糖尿病和肥胖症中，SGLT2 抑制剂和 GLP-1 受体激动剂的体重变化差异：机制可能性。
Obes Rev. 2019 Jun;20(6):816-828. doi: 10.1111/obr.12841. Epub 2019 Apr 10.
Zotero 插件